Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy - Are they drug specific or class specific?

Canadian Journal of Cardiology

Volumn 26, Issue SUPPL. E, 2010, Pages 15E-19E

  Burgess, Ellen ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

ACEI; ARB; Diabetes; Hypertension; Microalbuminuria; Nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INDAPAMIDE; IRBESARTAN; LOSARTAN; OLMESARTAN; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFECT; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MACROALBUMINURIA; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; STROKE; TREATMENT OUTCOME; ALBUMINURIA; HYPERTENSION; RISK ASSESSMENT; RISK FACTOR;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79958831765     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71169-7     Document Type: Review

References (23)

1. Campbell NR, Kaczorowski J, Lewanczuk RZ, et al. The 2010 Canadian Hypertension Education Program (CHEP) recommendations: The scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol 2010;26:236-40.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.
3. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl 1):S11-61.
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201.
5. McAlister FA, Laupacis A, Wells GA, Sackett DL; for the Evidence-Based Medicine Working Group. Users' guides to the medical literature XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7.
6. McDonagh MS, Eden KB, Peterson K. Drug Class Review on Calcium Channel Blockers: Final Report [Internet]. Portland (OR): Oregon Health & Science University, 2005.
7. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
8. Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5.
9. Ruggenenti P, Fassi A, Ilieva AP, et al; for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. New Engl J Med 2004;351:1941-51.
10. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; for the BENEDICT Study Group. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: A post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006;17:3472-81.
11. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet 2007;370:829-40.
12. de Galan BE, Perkovic V, Ninomiya T, Pillai A, et al; for the ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009;20:883-92.
13. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000;355:253-59.
14. Mann JFE, Schmieder RE, Dyal L, et al; for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators. Effect of telmisartan on renal outcomes. Ann Intern Med 2009;151:1-10.
15. Haller H, Viberti GC, Mimran A, Remuzzi G, et al. Preventing microalbuminuria in patients with diabetes: Rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. J Hypertens 2006;24:403-8.
16. Chaturvedi N, Porta M, Klein R, et al., for the DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
17. Sjølie AK, Klein R, Porta M, for the DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo-controlled trial. Lancet 2008;372:1385-93.
18. Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007;18:1889-98.
19. Parving H-H, Lehnert H, Brochner-Mortensen J, et al; for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med 2001;345:870-8.
20. Makino H, Haneda M, Babazono T, et al; for the INNOVATION Study Group. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007;30:1577-8.
21. Abbott Laboratories, Limited. MAVIK product monograph. Revised May 20, 2008.
22. Servier Canada, Inc. COVERSYL product monograph. Revised April 21, 2010.
23. Yu C, Gong R, Rifai A, Tolbert EM, Dworkin L.D. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: Nonhemodynamic renal protection. J Am Soc Nephrol 2007;18:750-9.